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During the influenza season 2007-8, the propor-
tion of seasonal influenza A(H1N1) viruses resistant 
to the neuraminidase inhibitor oseltamivir increased 
worldwide. We conducted an investigation to compare 
patients infected with oseltamivir-resistant (ose-R) 
and oseltamivir- susceptible (ose-S) influenza A(H1N1) 
viruses regarding risk factors for resistance and the 
capability to transmit in the household setting. Within 
a cohort of 396 laboratory confirmed influenza patients 
from sentinel physicians we conducted a nested case-
control study among patients infected with A(H1N1). 
Thirty patients in the cohort were infected with influ-
enza B, none with influenza A(H3N2) and 366 with 
A(H1N1). Of the 366 A(H1N1) viruses 52 (14%) were 
ose-R. Demographic characteristics, oseltamivir expo-
sure, travel history and outcome were not significantly 
different between ose-S and ose-R patients. Among 
133 households in the nested case-control study, sec-
ondary household attack rates in households with 
ose-R cases and households with ose-S cases were 
similar (23 versus 26%; p-value=0.54). Ose-R house-
hold status and occurrence of secondary cases were 
associated with an odds ratio of 0.85 (95% confidence 
interval 0.38-1.88). We conclude that seasonal ose-R 
influenza A(H1N1) viruses have transmitted well in the 
household setting.
Introduction
The neuraminidase inhibitors zanamivir and oseltami-
vir became available for the treatment and prophy-
laxis of influenza in 1999. Before the beginning of the 
influenza season 2007-8 in the northern hemisphere 
monitoring systems had identified resistance to osel-
tamivir in influenza viruses in less than 1%, and resist-
ance to zanamivir had been detected even less often 
[1,2]. Higher rates of resistance to oseltamivir were 
only reported in children in Japan (16%, 18%), where 
weight-based dosage is lower than approved in Europe 
and may have led to increased resistance rates [3,4]. 
Studies in ferrets showed that resistant viruses were in 
general less virulent and less transmissible in compari-
son to susceptible viruses [5-8]. 
In November 2007, Norway reported an unusually 
high proportion of seasonal influenza A(H1N1) viruses 
resistant to the neuraminidase inhibitor oseltamivir 
(ose-R). Soon after, other countries in Europe and the 
US also detected ose-R viruses [9]. Sequence analysis 
of viruses identified a substitution of tyrosine instead 
of histidine at residue 274 (H274Y in the N2 number-
ing) which conferred reduced drug sensitivity (IC50) 
of the viral enzyme neuraminidase. Susceptibility to 
zanamivir was maintained. In Europe, the weighted 
average proportion of ose-R among influenza A(H1N1) 
viruses increased over time from near zero in week 40 
(2007) to 56% in week 19 (2008) [9]. When the season 
2007-8 had subsided, 22 (73%) of 30 countries who 
had tested for oseltamivir resistance, had detected 
ose-R in A(H1N1) viruses (median among countries: 
10%; range: 0 - 67%) [10]. In addition, countries of the 
southern hemisphere reported the occurrence of ose-R 
influenza A(H1N1) viruses during their 2008 influenza 
season. In some of them the proportion of resistant 
viruses exceeded that found in European countries, for 
example in South Africa (100%; 225 of 225) [11], and 
Australia (80%; 47/59) [12]. During the influenza sea-
son 2008-9 close to 100% resistance was reported 
from European countries [13]. 
In March 2008, the European Centre for Disease 
Prevention and Control (ECDC) called a meeting with 
several European countries, to discuss the most salient 
questions around the new phenomenon. Following this, 
we launched an investigation (i) to compare the clini-
cal characteristics and outcome of patients infected 
with ose-R and ose-S influenza A(H1N1) viruses, (ii) to 
investigate if – prior to the sample having been taken 
– patients with ose-R A(H1N1) viruses had been treated 
with oseltamivir more frequently than patients with 
ose-S A(H1N1) virus infections, (iii) to investigate if the 
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occurrence of ose-R A(H1N1) virus infections was asso-
ciated with exposure to an influenza-infected person in 
the household who was treated with oseltamivir, (iv) to 
examine if patients infected with ose-R A(H1N1) viruses 
were more likely to have had travelled abroad prior to 
infection more frequently compared with patients with 
ose-S A(H1N1) viruses, and (v) to explore the transmis-
sibility of ose-R A(H1N1) viruses in comparison to ose-S 
A/H1N1 viruses in the household setting.
Methods 
Cohort study
We used data from 396 laboratory confirmed influ-
enza patients for whom samples (nose and/or throat 
swabs) were sent for laboratory investigation to the 
National Reference Centre for Influenza (NRCI) at the 
Robert Koch Institute (RKI, German national public 
health institute), Berlin by sentinel physicians coop-
erating with the German network for influenza surveil-
lance (Arbeitsgemeinschaft Influenza; www.influenza.
rki.de/agi). These patients are referred to as “sentinel 
cases”. Together with the samples, information is col-
lected routinely on the date of illness onset, age, sex, 
location of the treating physician, presenting symp-
toms, influenza vaccination status, and willingness to 
be contacted by the RKI and telephone number in case 
of a positive reply. 
Nested case-control study
To obtain information on pre-existing medical condi-
tions, travel history, intake of oseltamivir prior to taking 
the sample, exposure to oseltamivir through a house-
hold contact, complications or outcome (otitis, pneu-
monia, hospitalisation, death, duration of sick leave 
and number of days confined to bed), household size 
and the occurrence of influenza-like illness (ILI) in the 
household on the same day or five days before or after 
onset of illness in the sentinel case, we attempted to 
contact (i) all sentinel cases with an ose-R A(H1N1) virus 
infection, and (ii) a subset of sentinel cases infected 
with ose-S A(H1N1) viruses. This subset consisted of 
patients who had previously agreed to be contacted 
and had provided their telephone number. Interviewers 
conducted a questionnaire with the respective patients 
or, in the case of minors, their guardians. Interviewees 
were blinded to the susceptibility status of the virus of 
the sentinel case. Households were contacted between 
one and five months after occurrence of the laboratory 
confirmed household case.
Data were entered into a Microsoft Access database 
(Microsoft Corp., Redmond, WA, USA). Analysis was 
performed using STATA version 10.1 (STATA Corp., 
College Station, TX, USA). For categorical variables we 
calculated univariate odds ratios and p-values using 
Fisher’s exact test. Numerical variables were analysed 
using a ranksum test. 
Figure 1
Transmission of seasonal influenza A(H1N1) viruses 
in two exemplary households (A and B), study on 
transmission of oseltamivir-resistant seasonal influenza 
A(H1N1) viruses in household settings, Germany 2008
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The arrow heads indicate the onset of influenza-like illnes of 
household contacts (black arrows) and of the sentinel cases 
(laboratory confirmed; blue arrows). Day 0: onset of illness of 
sentinel cases.
Figure 2
Proportion of seasonal influenza A(H1N1) viruses 
resistant to oseltamivir among patient samples taken by 












































Patients with oseltamivir-susceptible and oseltamivir-resistant seasonal influenza A(H1N1) viruses by age group, cohort of 
patients attended by sentinel physicians (sentinel cases), Germany, influenza season 2007-8 (n=358)
Number of patients infected with oseltamivir-
susceptible influenza A(H1N1) viruses (%)
Number of patients infected with oseltamivir-
resistant influenza A(H1N1) viruses (%) Total
0-4 years 52 (88%) 7 (12%) 59
5-14 years 133 (87%) 19 (13%) 152
15-34 years 65 (83%) 13 (17%) 78
35 years and older 57 (83%) 12 (17%) 69
Total 307 (86%) 51 (14%) 358
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For the analysis of the likelihood to transmit the virus 
within the household we conducted a multilevel analy-
sis with levels person and household. In this context 
we defined the following terms:
Household transmission period (HTP): period from five 
days before until five days after the illness onset in 
sentinel cases, in total 11 days.
Household transmission: occurrence of at least one 
secondary case within the HTP after a primary case of 
ILI or laboratory-confirmed influenza (Figure 1).
Influenza-like illness (ILI) in a household contact: ill-
ness in a household contact of the sentinel case during 
the HTP with (i) subjective feeling of having fever; and/
or (ii) cough and (myalgia or headache).
Table 3
Associations of pre-existing medical conditions, risk factors and complications or outcome variables with oseltamivir 
susceptibility status of seasonal influenza A(H1N1) cases, nested case-control study, Germany, influenza season 2007-8
Exposure

























Diabetes 38 1 3% 95 0 0% - [0.00–∞] 0.29
Chronic heart disease 38 0 0% 95 0 0% - - -
Chronic lung disease 38 3 8% 95 3 3% 2.63 [0.33–20.40] 0.35
Chronic 
immuno-suppression 38 0 0% 95 0 0% - - -
Risk factors
Travel history 38 1 3% 95 2 2% 1.26 [0.02–24.78] 1.00
Oseltamivir treatment 
or prophylaxis before 
sample was taken




37 0 0% 95 1 0% 0 [0.00–∞] 1.00
Complications or outcome variables
Otitis 38 0 0% 95 4 4% 0 [0.00–2.38] 0.58
Pneumonia 38 2 5% 94 0 0% - [1.32–∞] 0.08
Hospitalisation 38 0 0% 95 0 0% - - -
Death 38 0 0% 95 0 0% - - -
Duration of sick leave  
in days a 11 7 (6–14) 26 7 (7–10) 0.74
Number of days 
confined to bed a 38     3.5 (2–7) 93     3 (2–5)     0.12
CI: confidence interval; IQR: interquartile range; OR: odds ratio; ose-R: oseltamivir resistant seasonal influenza A(H1N1) viruses; ose-S: 
oseltamivir susceptible seasonal influenza A(H1N1) viruses.
a For continuous variables a ranksum test was used. 
Table 2
Age, sex, vaccination status and symptoms of patients with seasonal influenza A(H1N1) viruses by sensitivity to oseltamivir, 
cohort of patients attended by sentinel physicians (sentinel cases), Germany, influenza season 2007-8 (n=343) 
 
Variable present Variable not present








Age (>14 years) 147 25 (17%) 211 26 (12%) 1.38 [0.83–2.29] 0.22
Male sex 192 32 (17%) 171 20 (12%) 1.43 [0.85–2.40] 0.23
Vaccination 17 2 (12%) 340 49 (14%) 0.82 [0.22–3.08] 1.00
Symptoms
Acute onset 352 50 (14%) 6 1 (17%) 0.85 [0.14–5.19] 1.00
Cough 336 49 (15%) 19 1 (5%) 2.77 [0.40–19.00] 0.49
Fever 353 51 (14%) 9 1 (11%) 1.3 [0.20–8.40] 1.00
Muscle, limb, body pain 330 49 (15%) 13 2 (15%) 0.97 [0.26–3.54] 1.00
CI: confidence interval; ose-R: oseltamivir resistant seasonal influenza A(H1N1) viruses; ose-S: oseltamivir-susceptible seasonal influenza 
A(H1N1) viruses.
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Primary case: first case in the household during the 
HTP with either ILI or laboratory-confirmed influenza. 
Secondary case: occurrence of at least one other case 
following the primary case during the HTP.
Different from the sentinel cases, additional household 
cases were identified through interviews only and were 
not laboratory tested for influenza. We assumed that 
(i) within the HTP resistance status did not change, i.e. 
we applied the resistance status of the sentinel case 
also to other household contacts if they became cases, 
and that (ii) within the HTP secondary cases occurred 
only from infection within the household and not from 
the community. 
On household level we used as explanatory variables 
household size and age and sex of the primary case. 
Moreover, treatment of this patient with oseltami-
vir, whether the influenza virus causing infection was 
ose-R, and date of illness onset were used as addi-
tional explanatory variables.
Laboratory testing
Susceptibility testing to oseltamivir was conducted at 
the NRCI using either a genotypic test for the H274Y-
mutation, and/or the phenotypic neuraminidase sus-
ceptibility analysis, as described previously [14]. 
Results 
Cohort study
Of the 396 patients with laboratory confirmed influ-
enza infection, 366 (92%) were infected with seasonal 
influenza A(H1N1), none with A(H3N2) and 30 (8%) 
with influenza B. None of the influenza B viruses were 
ose-R. Further analysis was restricted to 366 sentinel 
cases with influenza A(H1N1). Of these, age was known 
for 358 (98%) patients, ranging from one to 78 years 
and patients were categorised in the following age 
groups: 0–4 years (n= 59; 17%), 5–14 years (n= 152; 
42%), 15–34 years (n=78; 22%), 35 years or older (n= 
69; 19%). Sex was known for 363 (99%) patients, 192 
(47%) were male, 171 (53%) female. Onset of symptoms 
was between 6 December 2007 and 19 March 2008; 
87% of cases occurred in January and February. Patient 
samples came from all 16 German states except one 
(Mecklenburg-Western Pomerania).    
Overall, 52 (14%) patients were infected with an ose-R 
virus. The proportion of patients with ose-R virus infec-
tions  rose over time (p-value = 0.02) and reached 28% 
in March 2008 (Figure 2). 
There were no significant differences in age or sex 
between patients with and without ose-R virus infec-
tions, even though the proportion of patients infected 
with ose-R viruses increased slightly with age (Table 1). 
Also regarding symptoms and vaccination status there 
was no statistically significant difference (Table 2). 
Table 4
Univariate and multivariate analysis of explanatory variables for secondary household cases with influenza-like illnessa 
(multilevel model, see text), nested case-control study, Germany, influenza season 2007-8
Univariate Multivariate
OR 95% CI p-value OR 95% CI p-value
Oseltamivir resistance of primary case 0.85 0.38–1.88 0.69 0.72 0.31–1.69 0.45
Treatment of primary case with oseltamivir 0.68 0.31–1.51 0.34 0.62 0.28–1.40 0.25
Male sex of primary case 0.83 0.42–1.63 0.59 1.12 0.56–2.25 0.75
Date of symptom onset of the primary case 0.99 0.97–1.01 0.33 0.99 0.97–1.01 0.36
Household with two persons 2.43 0.76–7.79 0.13 3.94 1.05–14.82 0.04
Age group of primary case
0-4 years 0.63 0.19–2.04 0.44 0.56 0.16–1.99 0.37
5-14 years 0.67 0.26–1.74 0.41 0.85 0.32–2.28 0.75
15-34 years 0.38 0.12–1.27 0.12 0.53 0.16–1.74 0.29
35 years and older 1 (Reference) - 1 (Reference) -
CI: confidence interval; OR: odds ratio.
a All cases in the period of five days before until five days after onset of disease of sentinel case, in total period of 11 days.
Figure 3
Frequency distribution of secondary household attack 
rates by oseltamivir susceptibility status of the households, 
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Of 52 ose-R patients, 38 (73%) could be contacted for 
a telephone interview either because they had agreed 
to be contacted (n=22) or were asked by their physi-
cian to get in contact with us (n=16). Of 105 ose-S 
patients who were willing to be contacted by telephone 
we reached 95 (90%). No statistically significant differ-
ence regarding age or sex was found between patients 
who had agreed to be contacted by our institute and 
those who did not. Therefore, we included 133 patients 
(38 ose-R, 95 ose-S) in the calculations for the nested 
case-control study. 
Odds ratios and p-values for pre-existing medical con-
ditions, travel history, exposure to oseltamivir (patient 
him/herself or through household contact), complica-
tions and outcome are displayed in Table 3. Overall, 39 
(34%) of 114 were treated with oseltamivir. No patient 
with ose-R influenza and only one patient with ose-S 
influenza had taken oseltamivir before the respira-
tory sample was taken. Similarly, no patient with an 
ose-R infection and one patient with an ose-S infection 
was exposed to a household contact who had taken 
oseltamivir. Two cases of pneumonia occurred among 
patients with ose-R influenza, none among infected 
with ose-S viruses. The number of days that patients 
were bedridden was higher in patients with an ose-R 
virus infection (mean 4.6 days versus 3.4 days; p-value 
= 0.12). When this variable was stratified by age and 
sex there was no difference among the groups except 
for males less than five years old, where the median 
for patients with ose-R viruses was five (interquartile 
range, IQR: 1.5–7; n=4) and the median for patients 
with ose-S viruses 0.5 days (IQR: 0–2; n=6). 
Household transmission 
Information on household size was available for 132 
(99%) of 133 households. The median number of  per-
sons per household was four (IQR:  3–4; n=132). The 
number of household members in ose-S and ose-R 
households did not differ significantly (p-value = 0.2). 
Overall, the secondary attack rate in households was 
25.4% (89/350); in households with ose-S patients 
(ose-S household) it was 26.2% (71/271) compared with 
22.8% (18/79) in ose-R households (p-value = 0.54) 
(Figure 3). In univariate analysis ose-R of the house-
hold was not significantly associated with household 
transmission (Table 4), neither were date of infection, 
treatment of the primary case with oseltamivir, living 
in a two-person household or male sex of the primary 
case. Furthermore, there was also no trend (in terms 
of increasing or decreasing odds ratios) associated 
with increasing age of the primary case. In multivari-
ate analysis none of the above variables except living 
in a two-person household were significantly associ-
ated with increased household transmission. The vari-
ance of the random effect for household was estimated 
as 0.86 (0.27–2.78), and this model was significantly 
better fitting the data than a usual logistic regression 
model that does not account for the household struc-
ture (p-value < 0.01).
Discussion
Our study took place during the influenza season 
2007-8 and focuses on the seasonal influenza A(H1N1) 
virus circulating at the time, i.e. before the appear-
ance of the 2009 pandemic influenza A(H1N1) virus. 
Nevertheless, the conclusions that can be drawn from 
our study are of importance also in the context of the 
2009 pandemic influenza. Using household based 
data we demonstrate formally and convincingly that 
the ose-R seasonal influenza A(H1N1) virus of that time 
was capable of being transmitted to the same extent 
as the ose-S virus. The 2009 pandemic virus is also a 
subtype A(H1N1) virus. It is therefore possible at any 
time that the pandemic virus may become resistant 
to oseltamivir while maintaining transmissibility and 
pathogenicity similar to the seasonal A(H1N1) virus in 
the influenza seasons 2007-8 and 2008-9.
The occurrence of secondary cases in households of 
patients with an ose-R infection in our study can be 
interpreted as evidence of transmission of ose-R virus 
in the household setting. In addition, as secondary 
household attack rates and the odds for a secondary 
case were similar in ose-R and ose-S households there 
is evidence that ose-R and ose-S viruses do not differ 
considerably in their capacity to transmit within the 
household setting. Analysis of demographic charac-
teristics and other factors related to the primary case 
or household showed that treatment of the primary 
case with oseltamivir did not inhibit transmission sig-
nificantly. As the proportion of ose-R viruses increased 
over time, it was interesting to know if date of infection 
was associated with an increased transmission prob-
ability. However, we did not find any time trend in this 
regard. Although the power of our study was too low to 
show any difference (if it exists), the point estimates 
and p-values of investigated factors did not indicate 
that they are of relevance. Nevertheless, if transmis-
sion is as likely for ose-R viruses as it is for ose-S 
viruses it remains unclear why the proportion of ose-R 
A(H1N1) viruses has increased over the course of the 
2007-8 season not only in Germany, but also in other 
countries in Europe [15]. As we have measured trans-
mission in households only it is possible that differ-
ences in transmission in the community account for the 
increasing dominance of resistant viruses. 
  
Although van der Vries et al. have described a fatal 
case of ose-R A(H1N1) infection in a man with chronic 
lymphocytic leukemia [16], systematic comparisons of 
the outcome of ose-S and ose-R infections in European 
countries and the United States (US) have not sug-
gested a difference in clinical outcome [17-19]. Similarly 
we also found no different pathogenicity of ose-R 
viruses compared with ose-S viruses, when measured 
by complications (otitis, pneumonia) or outcome.
Oseltamivir resistance was also not associated with 
exposure to oseltamivir, neither through treatment 
or prophylaxis before sampling of the sentinel case 
nor through exposure from any of his/her household 
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contacts. Thus, our data do not indicate that drug 
pressure has led to the emergence of ose-R viruses 
in individual patients. This finding is consistent with 
patient-level data from the US [18] and ecological state 
or nation-level data from the US and Europe, respec-
tively, where increased ose-R rates in influenza A(H1N1) 
viruses were not associated with increased levels of 
prescriptions of oseltamivir [18,20].  
Lastly, in our data there was no sign that travel his-
tory was associated with the emergence of oseltami-
vir resistance. As most sequenced European ose-R 
A(H1N1) viruses are closely related and belong to a 
separate group, distinct from that of ose-S viruses, it is 
likely that they originate from a single variant [9] which 
at some point before the start of the season had been 
imported, from an unknown location, and was trans-
mitted in the community afterwards. We would there-
fore expect to find no association with foreign travel. 
Our study has some limitations. Additional house-
hold cases were not laboratory confirmed but were 
identified through a symptom-based unspecific case 
definition only. This may have led to over- or underes-
timation of the true number of additional household 
infections. However, it is unlikely that information bias 
has occurred because this limitation applies equally to 
ose-S and ose-R households. The time interval between 
disease of the sentinel case and interview was variable 
and sometimes long. This may have reduced the abil-
ity of interviewees to remember details asked in the 
questionnaire. Again, this did not happen differentially 
in one or another group and should have therefore not 
resulted in distorted effect measures.  
In conclusion, analysis of our data from the influenza 
season 2007-8 suggests that there is no indication of 
an association of oseltamivir exposure and/or use and 
the occurrence of ose-R seasonal influenza A(H1N1) 
viruses. Ose-R viruses seem to be as pathogenic as 
ose-S viruses. We have found evidence of and have 
quantified transmission of ose-R A(H1N1) viruses in 
the household setting and its degree is comparable 
to that in ose-S viruses. This information is important 
to understand the epidemiology of ose-R viruses, but 
more work needs to be done to fully comprehend the 
reasons for the increase of the prevalence of ose-R 
among A(H1N1) viruses over the two influenza seasons 
2007-8 and 2008-9.
Acknowledgements
We thank Franziska Schwarz for her administrative support; 
Manuela Friedrich for her excellent technical assistance; 
Melanie Helmig and Stefanie Fehrendt for conducting tel-
ephone interviews; the sentinel physicians for taking patient 
samples for virological testing.
References
1. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, 
Hay A, Klimov A, et al. Detection of influenza viruses resistant 
to neuraminidase inhibitors in global surveillance during 
the first 3 years of their use. Antimicrob Agents Chemother. 
2006;50(7):2395-402. 
2. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, 
Bright RA, et al. Surveillance for neuraminidase inhibitor 
resistance among human influenza A and B viruses circulating 
worldwide from 2004 to 2008. Antimicrob Agents Chemother. 
2008;52(9):3284-92. 
3. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir 
(Tamiflu) and its potential for use in the event of an influenza 
pandemic. J Antimicrob Chemother. 2005;55 Suppl 1:i5-i21. 
4. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza 
A viruses in children treated with oseltamivir: descriptive 
study. Lancet. 2004;364(9436):759-65. 
5. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel, et 
al. Influenza virus carrying neuraminidase with reduced 
sensitivity to oseltamivir carboxylate has altered properties in 
vitro and is compromised for infectivity and replicative ability 
in vivo. Antiviral Res. 2002;54(2):79-88. 
6. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, 
et al. Influenza virus carrying an R292K mutation in the 
neuraminidase gene is not transmitted in ferrets. Antiviral Res. 
2002;54(2):99-111. 
7. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in 
the influenza A/H1N1 neuraminidase active site following 
oseltamivir phosphate treatment leave virus severely 
compromised both in vitro and in vivo. Antiviral Res. 
2002;55(2):307-17. 
8. Carr J, Roberts N, Herlocher L. (2002). Further study of the 
transmission in ferrets of influenza A/H1N1 virus carrying 
a H274Y neuraminidase mutation for Tamiflu®, oseltamivir 
phosphate; Roche Research Report 1008171.
9. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, 
Schweiger B. Oseltamivir-resistant influenza A (H1N1) virus, 
Europe, 2007–08 season. Emerg Infect Dis. 2009;15(4):552-60. 
10. EISS. European Influenza Surveillance Scheme. EISS update 
from August 27, 2008.[Accessed on: Nov 24, 2008]. Later 
updates available from: http://webportal.ecdcdmz.europa.eu/
en/activities/surveillance/EISN/Pages/home.aspx.
11. Besselaar TG, Naidoo D, Buys A, Gregory V, McAnerney J, 
Manamela JM, et al. Widespread oseltamivir resistance in 
influenza A viruses (H1N1), South Africa. Emerg Infect Dis. 
2008;14(11):1809-10. 
12. World Health Organization (WHO). [Internet]. Geneva; 2008. 
Influenza A/H1N1 virus resistance to oseltamivir - 2008 
influenza season, southern hemisphere. [Accessed on: Dec 01, 
2008]. Available from: www.who.int/csr/disease/influenza/
H1N1200801013.pdf.
13. European Centre for Disease Prevention and Control (ECDC). 
[Internet]. Stockholm; 2009. Monitoring of influenza antiviral 
resistance in EU during the 2008-09 season. [Accessed on: Feb 
20, 2009]. Available from: http://ecdc.europa.eu/en/Health_
topics/influenza/antivirals.aspx. 
14. Duwe S, Schweiger B. A new and rapid genotypic assay for 
the detection of neuraminidase inhibitor resistant influenza A 
viruses of subtype H1N1, H3N2, and H5N1. Journal of virological 
methods. 2008;153(2):134-41. 
15. EISS. European Influenza Surveillance Scheme. EISS updates. 
[Accessed on: Dec 01, 2008]. Later updates available 
from: http://webportal.ecdcdmz.europa.eu/en/activities/
surveillance/EISN/Pages/home.aspx.  
16. van der Vries E, van den Berg B, Schutten M. Fatal 
oseltamivir-resistant influenza virus infection. N Engl J Med. 
2008;359(10):1074-6. 
17. Ciancio BC, Meerhoff TJ, Kramarz P, et al. Oseltamivir-
resistant influenza A(H1N1) viruses detected in Europe during 
season 2007-8 had epidemiologic and clinical characteristics 
similar to co-circulating susceptible A(H1N1) viruses. Euro 
Surveill. 2009;14(46). pii= 19412. Available from: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=19412. 
18. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, 
McClinton RC, Marshall SA et al. Infections with oseltamivir-
resistant influenza A(H1N1) virus in the United States. JAMA. 
2009;301(10):1034-41. 
19. Hauge S, Dudman S, Borgen K, Lackenby A, Hungnes O. 
Oseltamivir-resistant influenza viruses A(H1N1), Norway, 2007-
08. Emerg Infect Dis. 2009;15(2):155-62. 
20. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of 
oseltamivir in 12 European countries between 2002 and 2007 - 
lack of association with the appearance of oseltamivir-resistant 
influenza A(H1N1) viruses. Euro Surveill. Feb 5 2009;14(5). 
pii=19112. Available from: http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=19112
